Combined immunotherapy in lung cancer — a case report highlighting immune response dynamics and clinical success
, 1, 1, 1, 1
Abstract
Immunotherapy with the use of immune checkpoint inhibitors (ICIs) is one of the key therapeutic options in cancer, especially in advanced non-small cell lung cancer (NSCLC). The combination of chemotherapy and immunotherapy — nivolumab (anti-programmed death-1, anti-0PD-1) and ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4, anti-CTLA-4) — has been found beneficial in clinical trials addressing advanced NSCLC. Here, we present a case of a female patient with PD-1 ligand (PD-L1)-negative, advanced squamous-cell carcinoma with a long response to chemoimmunotherapy. The patient had several episodes of adverse events and exacerbation of autoimmune disease. An analysis of immunological background was performed, and it revealed changes in the percentages of certain immune cell subpopulations in the patient’s blood during immunotherapy.
Keywords: chemoimmunotherapynivolumabipilimumabNSCLClymphocytes subpopulations
References
- Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023; 22(1): 40.
- Frisone D, Friedlaender A, Addeo A, et al. The Landscape of Immunotherapy Resistance in NSCLC. Front Oncol. 2022; 12: 817548.
- Lin Li, Liu Yu, Chen C, et al. Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis. Front Pharmacol. 2023; 14: 1190001.
- Gao W, Liu Q, Zhou Y, et al. The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy. Technol Cancer Res Treat. 2023; 22: 15330338231206705.
- Ponvilawan B, Khan AW, Subramanian J, et al. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors. Cancers (Basel). 2024; 16(6).
- Reck M, Ciuleanu TE, Dols M, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol. 2020; 38(15_suppl): 9501–9501.
- Reck M, Ciuleanu TE, Schenker M, et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024; 211: 114296.
- Kimura N, Tsukita Y, Ebina-Shibuya R, et al. Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC. Cancer Biomark. 2024 [Epub ahead of print].
- Tian T, Li Z. Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade. Front Oncol. 2021; 11: 731175.
- Kuziel WA, Morgan SJ, Dawson TC, et al. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci U S A. 1997; 94(22): 12053–12058.
- Intlekofer AM, Takemoto N, Wherry EJ, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol. 2005; 6(12): 1236–1244.
- Krizova L, Benesova I, Zemanova P, et al. Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors. J Cancer Res Clin Oncol. 2024; 150(2): 99.
- Zhen S, Wang W, Qin G, et al. Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy. Front Immunol. 2024; 15: 1316778.
- Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018; 128(2): 715–720.
- Wang Z, Zhan P, Lv Y, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl Lung Cancer Res. 2019; 8(3): 214–226.